Navigation Links
Vermillion Announces First Quarter 2008 Financial Results and Business Progress
Date:5/15/2008

from $5.7 million in the same period last year. The decrease was due primarily to restructuring of personnel and reduced general and administrative expenses.

The Company's net loss for the first quarter of 2008 was $4.8 million, compared to $6.0 million for the same period in 2007. Basic and diluted net loss for the first quarter of 2008 was $0.76 per share based on 6.38 million total shares outstanding, compared to a basic and diluted net loss of $1.54 per share based on 3.92 million total shares outstanding for the same period in 2007. Earnings per share calculations are on a post reverse stock split basis.

At March 31, 2008, the Company's cash, short- and long-term investments totaled $14.3 million, compared to $20.4 million at December 31, 2007. Net cash used in operating activities in the first quarter of 2008 was $5.5 million. The semi-annual payment of interest of approximately $0.6 million on the senior convertible note is due during the first and third quarters, which results in higher net cash outflows for these quarters. Vermillion continues to diligently manage expenses and cash utilization.

Recent Highlights and Accomplishments

During the first and into the second quarter of the year, Vermillion achieved numerous milestones in its three leading diagnostic programs and continued to progress in its corporate development efforts.

-- PAD Diagnostic Program

* Established a clinical steering committee to provide advice on

studies to support registration of VASCLIR with the FDA and to

further potential market adoption.

* Presented data from a study providing further confirmation that the

Company's test may aid in the diagnosis of PAD. The research, which

was presented at the American College of Cardiology 57th Annual

Scientific Session, suggests that such a test may be useful in

helping determine a patient's risk for de
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Vermillion (Formerly Ciphergen) Announces $20.5 Million Private Placement of Common Stock
2. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
3. Vermillion, Inc. Announces Receipt Of Notice Of Compliance From Nasdaq
4. Vermillion to Webcast Presentation at the Acumen BioFin 9th Annual Healthcare Conference, November 5-7, New York
5. Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests
6. Vermillion Receives NASDAQ Notice of Non-Compliance
7. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
8. Vermillion Announces Effectiveness of Reverse Stock Split
9. Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones
10. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
11. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... 27, 2014 The new research ... (High & Medium), Sub-type (Primary & Secondary), and ... & Transportation & Power Generation) - Trends and ... market with analysis and forecasting of the market ... Tables with 52 Figures spread through 146 Pages ...
(Date:10/27/2014)... TORONTO , Oct. 27, 2014 ... (OTCQB: GNBT) today announced two presentations demonstrating that ... its novel proprietary cancer immunotherapeutic AE37 vaccine correlated ... patients. The AE37 cancer vaccine is being developed ... ( www.antigenexpress.com ). The presentations are being made ...
(Date:10/27/2014)... 27, 2014 The “Molecular Diagnostic ... Microbiology), Technology (PCR, INAAT, DNA Sequencing), End User ... Software) - Global Forecast to 2018” provides a ... opportunities, current market trends, and strategies impacting the ... and forecasts of the revenue and share analysis. ...
(Date:10/27/2014)... 27, 2014 Called the NOAH ... eliminating several types of pediatric brain cancer. The ... in over 30 years of research and development. ... proves that one mom's determination can make a ... Halloween trick-or-treating, and it’s only fitting that we’ve ...
Breaking Biology Technology:Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3
... Calif., Feb. 17 Avantis Medical Systems, Inc., a ... announced today that it has received a new 510(k) ... the claim for increased detection of cancerous and pre-cancerous ... technology that has been cleared by the FDA to ...
... as Senior Scientist , BURLINGTON, Mass., ... expansion of its executive team with the appointment ... The company also announced the addition of Richard ... )The appointments reflect the evolution of the company,s ...
... LIMMERICK, Ireland, Feb. 16 Copan Innovation Ltd., whose ... collection and transport systems in the world, has named ... Development in the Pacific Rim, as well as appointed ... Innovation Ltd. Bob Cooper, who brings a background of ...
Cached Biology Technology:Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon 2Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon 3Avantis Medical Systems Announces FDA 510(k) Clearance for the Third Eye(R) Retroscope(R) for Improved Polyp Detection in the Colon 4CorNova(R) Expands Management Team with Appointment of Robert Gallahue as Chief Financial Officer 2Copan Announces the Appointment of Bob Cooper as Vice President of Business Development in the Pacific Rim 2
(Date:10/29/2014)... of kidney cancer patients in Europe sheds light on ... an apparent link between exposure to aristolochic acid and ... research, by an international team led by scientists from ... Montreal, underscores the importance of investigating possible sources of ... of the Aristolochia genus, also has been suspected of ...
(Date:10/28/2014)... German . , ... food when times are lean? By studying wild chimpanzees ... of the Max Planck Institute for Evolutionary Anthropology in ... apes can acquire extra energy needed to maintain large, ... nests more en route to breakfast sites containing fruits ...
(Date:10/28/2014)... of Health (NIH) announced awards to expand the ... National Center for Advancing Translational Sciences (ORDR-NCATS) collaborative ... the network, physician scientists at 22 consortia will ... clinical research and investigate new treatments for patients ... by $29 million in fiscal 2014 funding from ...
Breaking Biology News(10 mins):Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3The early chimp gets the fig 2The early chimp gets the fig 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3
... IN Traditional turfgrass management programs rely heavily ... In response to increased public scrutiny and legislation, ... but research indicates that these alternatives have not ... lawn care industry. Results of a new study ...
... as the great pandemia of the XXI century. Recent data ... suffering from overweight, of which 300 million are clinically obese. ... worrying increase, with more than 155 million children and adolescents ... Biologist Aline Jelenkovic analysed to what point corporal morphology was ...
... QUEBEC, CANADA A study in HortTechnology ... reducing solar heat radiation and temperatures during the hot ... Canadian researchers, was the first investigation into the effects ... shading method. Results showed that the technology improved greenhouse ...
Cached Biology News:Turfgrass fertility, pesticide programs compared 2The amount of adipose tissue should be taken into account in the fight against obesity 2The amount of adipose tissue should be taken into account in the fight against obesity 3New technology improves greenhouse, plant microclimates 2
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
chk 1 kinase...
muscle actin (HUC1-1)...
... Neural Stem Cell Functional Identification Kit ... can be used for the short-term ... and the induction of NSCs into ... antibody panel consisting of mouse anti-human ...
Biology Products: